NO20011454L - Fremgangsmåter ved administrering av antibiotika - Google Patents
Fremgangsmåter ved administrering av antibiotikaInfo
- Publication number
- NO20011454L NO20011454L NO20011454A NO20011454A NO20011454L NO 20011454 L NO20011454 L NO 20011454L NO 20011454 A NO20011454 A NO 20011454A NO 20011454 A NO20011454 A NO 20011454A NO 20011454 L NO20011454 L NO 20011454L
- Authority
- NO
- Norway
- Prior art keywords
- administering
- daptomycin
- muscle toxicity
- skeletal muscle
- effective amount
- Prior art date
Links
- 239000003242 anti bacterial agent Substances 0.000 title abstract 2
- 229940088710 antibiotic agent Drugs 0.000 title abstract 2
- 231100000483 muscle toxicity Toxicity 0.000 abstract 6
- 108010013198 Daptomycin Proteins 0.000 abstract 5
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 abstract 5
- 229960005484 daptomycin Drugs 0.000 abstract 5
- 210000002027 skeletal muscle Anatomy 0.000 abstract 4
- 108010028921 Lipopeptides Proteins 0.000 abstract 2
- PPKJUHVNTMYXOD-PZGPJMECSA-N c49ws9n75l Chemical compound O=C([C@@H]1N(C2=O)CC[C@H]1S(=O)(=O)CCN(CC)CC)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(\C)=C\[C@@H](O)CC(=O)CC1=NC2=CO1.N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O PPKJUHVNTMYXOD-PZGPJMECSA-N 0.000 abstract 2
- 229940052337 quinupristin/dalfopristin Drugs 0.000 abstract 2
- 230000003115 biocidal effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10182898P | 1998-09-25 | 1998-09-25 | |
| US12575099P | 1999-03-24 | 1999-03-24 | |
| PCT/US1999/022366 WO2000018419A2 (en) | 1998-09-25 | 1999-09-24 | Methods for administration of antibiotics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20011454D0 NO20011454D0 (no) | 2001-03-22 |
| NO20011454L true NO20011454L (no) | 2001-05-25 |
Family
ID=26798675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20011454A NO20011454L (no) | 1998-09-25 | 2001-03-22 | Fremgangsmåter ved administrering av antibiotika |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US6468967B1 (https=) |
| EP (2) | EP1674107B8 (https=) |
| JP (4) | JP4184607B2 (https=) |
| KR (2) | KR20100051735A (https=) |
| CN (2) | CN1150029C (https=) |
| AT (1) | ATE322280T1 (https=) |
| AU (1) | AU764348B2 (https=) |
| BR (1) | BR9914051A (https=) |
| CA (1) | CA2344318C (https=) |
| CY (3) | CY1105556T1 (https=) |
| DE (3) | DE122006000049I2 (https=) |
| DK (2) | DK1115417T3 (https=) |
| ES (2) | ES2259845T3 (https=) |
| HK (1) | HK1040363B (https=) |
| HU (1) | HU230656B1 (https=) |
| IS (2) | IS5890A (https=) |
| LU (1) | LU91254I2 (https=) |
| NL (1) | NL300232I2 (https=) |
| NO (1) | NO20011454L (https=) |
| NZ (1) | NZ510690A (https=) |
| PL (2) | PL206091B1 (https=) |
| PT (2) | PT1674107T (https=) |
| RU (1) | RU2363489C9 (https=) |
| SI (2) | SI1115417T1 (https=) |
| TR (1) | TR200100841T2 (https=) |
| WO (1) | WO2000018419A2 (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122006000049I2 (de) | 1998-09-25 | 2007-11-08 | Cubist Pharm Inc | Verwendung von Daptomycin |
| MXPA02006029A (es) | 1999-12-15 | 2004-08-23 | Cubist Pharm Inc | Lipopeptidos novedosos como agentes antibacterianos. |
| US6696412B1 (en) | 2000-01-20 | 2004-02-24 | Cubist Pharmaceuticals, Inc. | High purity lipopeptides, Lipopeptide micelles and processes for preparing same |
| WO2002059145A1 (en) * | 2000-12-18 | 2002-08-01 | Cubist Pharmaceuticals, Inc. | Methods for preparing purified lipopeptides |
| NZ554405A (en) | 2000-12-18 | 2009-04-30 | Cubist Pharm Inc | Method for preparing crystalline and crystal-like forms of purified lipopeptides |
| US20060014674A1 (en) | 2000-12-18 | 2006-01-19 | Dennis Keith | Methods for preparing purified lipopeptides |
| EP1932853A1 (en) | 2001-08-06 | 2008-06-18 | Cubist Pharmaceutical Inc. | Novel depsipeptides and process for preparing same |
| AU2003274927A1 (en) * | 2002-08-23 | 2004-03-11 | Genome Therapeutics Corporation | Methods and reagents for preventing bacteremias |
| US20060074014A1 (en) * | 2002-11-18 | 2006-04-06 | Vicuron Pharmaceuticals Inc. | Dalbavancin compositions for treatment of bacterial infections |
| US20050277581A1 (en) * | 2002-11-18 | 2005-12-15 | Vicuron Pharmaceuticals Inc. | Dalbavancin compositions for treatment of bacterial infections |
| US20050220862A1 (en) * | 2004-03-31 | 2005-10-06 | Bernstein Joel E | Compositions with reduced hepatotoxicity |
| US20060004185A1 (en) * | 2004-07-01 | 2006-01-05 | Leese Richard A | Peptide antibiotics and peptide intermediates for their prepartion |
| US20060014677A1 (en) * | 2004-07-19 | 2006-01-19 | Isotechnika International Inc. | Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds |
| US20080051326A1 (en) * | 2004-11-12 | 2008-02-28 | Alexander Dylan C | Antiinfective Lipopeptides |
| US8546423B2 (en) | 2005-05-18 | 2013-10-01 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
| US7838532B2 (en) * | 2005-05-18 | 2010-11-23 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
| US20070238630A1 (en) * | 2006-03-29 | 2007-10-11 | Phillips Douglas H | Subcutaneous skin cleanser |
| EP2018864A1 (en) * | 2007-07-23 | 2009-01-28 | Biomet Deutschland GmbH | Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition |
| MX2010009628A (es) * | 2008-03-04 | 2010-09-28 | Elan Pharma Int Ltd | Formulaciones liquidas estables de agentes antiinfecciosos, y regimenes de dosificacion ajustados de los agentes antiinfecciosos. |
| CN102159236A (zh) | 2008-07-17 | 2011-08-17 | 阿索尔达治疗公司 | 用于治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂 |
| DE102008046610A1 (de) * | 2008-09-09 | 2010-03-11 | Biomet Deutschland Gmbh | Verwendung einer pharmazeutischen Zusammensetzung zur lokalen Infektionstherapie sowie Medizinprodukt |
| EP2346509B1 (en) | 2008-10-07 | 2020-05-13 | Horizon Orphan LLC | Inhalation of levofloxacin for reducing lung inflammation |
| JP2012505223A (ja) | 2008-10-07 | 2012-03-01 | エムペックス・ファーマシューティカルズ・インコーポレーテッド | 薬物動態の改善のためのエアゾールフルオロキノロン配合物 |
| US8809263B2 (en) * | 2008-10-24 | 2014-08-19 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Anti-infective hydroxy-phenyl-benzoates and methods of use |
| PL2379580T3 (pl) | 2008-12-22 | 2014-05-30 | Merck Sharp & Dohme | Nowe środki przeciwbakteryjne do leczenia zakażeń wywołanych bakteriami Gram-dodatnimi |
| CA2747995A1 (en) | 2008-12-23 | 2010-07-01 | Biosource Pharm, Inc. | Antibiotic compositions for the treatment of gram negative infections |
| US8450300B2 (en) * | 2009-07-13 | 2013-05-28 | Cempra Pharmaceuticals Inc. | Fusidic acid dosing regimens for treatment of bacterial infections |
| CA2767614C (en) * | 2009-07-13 | 2019-01-15 | Cempra Pharmaceuticals Inc. | Fusidic acid dosing regimens for treatment of bacterial infections |
| RU2563809C2 (ru) | 2009-09-04 | 2015-09-20 | Мпекс Фармасьютикалс, Инк. | Применение левофлоксацина в форме аэрозоля для лечения муковисцидоза |
| SG10201407724YA (en) | 2009-11-23 | 2014-12-30 | Cubist Pharm Inc | Daptomycin compositions and related methods |
| US8247394B2 (en) | 2010-06-02 | 2012-08-21 | Cempra Pharmaceuticals Inc. | Methods of treating urethritis and related infections using fusidic acid |
| US8415307B1 (en) | 2010-06-23 | 2013-04-09 | Biosource Pharm, Inc. | Antibiotic compositions for the treatment of gram negative infections |
| WO2013059610A1 (en) * | 2011-10-20 | 2013-04-25 | Trius Therapeutics, Inc. | Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use |
| US8940897B2 (en) | 2012-03-30 | 2015-01-27 | Cubist Pharmaceuticals, Inc. | 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors |
| HK1207006A1 (en) * | 2012-09-11 | 2016-01-22 | Hospira Australia Pty Ltd | Daptomycin formulations and uses thereof |
| CN103006562B (zh) * | 2013-01-21 | 2014-09-17 | 西南大学 | 达托霉素醇质体制剂 |
| CA2904387C (en) | 2013-03-15 | 2021-12-07 | Melinta Therapeutics, Inc. | Methods of treating infections in overweight and obese patients using antibiotics |
| US11667674B2 (en) | 2016-04-08 | 2023-06-06 | Versitech Limited | Antibacterial cyclic lipopeptides |
| US10647746B2 (en) | 2016-04-08 | 2020-05-12 | Versitech Limited | Antibacterial cyclic lipopeptides |
| JP2019515007A (ja) * | 2016-05-13 | 2019-06-06 | スペロ ポテンシエーター インコーポレイテッドＳｐｅｒｏ Ｐｏｔｅｎｔｉａｔｏｒ， Ｉｎｃ． | 新規カチオン性ペプチドｓｐｒ７４１による、抗生物質活性の増強 |
| CN114788814B (zh) * | 2021-01-26 | 2023-10-13 | 浙江创新生物有限公司 | 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998022107A1 (fr) * | 1996-11-19 | 1998-05-28 | Rhone-Poulenc Rorer S.A. | Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE32333E (en) | 1978-10-16 | 1987-01-20 | Eli Lilly And Company | A-21978 Antibiotics and process for their production |
| USRE32455E (en) | 1978-10-16 | 1987-07-07 | Eli Lilly And Company | A-21978 antibiotics and process for their production |
| US4524135A (en) | 1982-05-21 | 1985-06-18 | Eli Lilly And Company | A-21978C cyclic peptides |
| USRE32310E (en) | 1982-05-21 | 1986-12-16 | Eli Lilly And Company | Derivatives of A-21978C cyclic peptides |
| USRE32311E (en) | 1982-05-21 | 1986-12-16 | Eli Lilly And Company | Derivatives of A-21978C cyclic peptides |
| US4537717A (en) | 1982-05-21 | 1985-08-27 | Eli Lilly And Company | Derivatives of A-21978C cyclic peptides |
| US4482487A (en) | 1982-05-21 | 1984-11-13 | Eli Lilly And Company | A-21978C cyclic peptides |
| US4885243A (en) | 1984-10-09 | 1989-12-05 | Eli Lilly And Company | Process for producing A-21978C derivatives |
| US4800157A (en) | 1985-09-09 | 1989-01-24 | Eli Lilly And Company | Process for producing the A-21978C antibiotics |
| US4874843A (en) | 1987-12-03 | 1989-10-17 | Eli Lilly And Company | Chromatographic purification process |
| CA1315229C (en) | 1987-06-10 | 1993-03-30 | Eli Lilly And Company | Chromatographic purification process |
| EP0386951A3 (en) * | 1989-03-06 | 1992-05-20 | Eli Lilly And Company | An improved diluent formulation for daptomycin |
| FR2772272B1 (fr) | 1997-12-16 | 2000-01-14 | Rhone Poulenc Rorer Sa | Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation |
| DE122006000049I2 (de) | 1998-09-25 | 2007-11-08 | Cubist Pharm Inc | Verwendung von Daptomycin |
| US9393093B2 (en) | 2008-02-18 | 2016-07-19 | Covidien Lp | Clip for implant deployment device |
-
1999
- 1999-09-24 DE DE200612000049 patent/DE122006000049I2/de active Active
- 1999-09-24 DK DK99949913T patent/DK1115417T3/da active
- 1999-09-24 DK DK06006697.4T patent/DK1674107T3/en active
- 1999-09-24 DE DE1999630758 patent/DE122006000049I1/de active Pending
- 1999-09-24 KR KR1020107006807A patent/KR20100051735A/ko not_active Ceased
- 1999-09-24 SI SI9930904T patent/SI1115417T1/sl unknown
- 1999-09-24 SI SI9931082A patent/SI1674107T1/sl unknown
- 1999-09-24 US US09/406,568 patent/US6468967B1/en not_active Expired - Lifetime
- 1999-09-24 HK HK02100152.2A patent/HK1040363B/en not_active IP Right Cessation
- 1999-09-24 AU AU62687/99A patent/AU764348B2/en not_active Expired
- 1999-09-24 PL PL384274A patent/PL206091B1/pl unknown
- 1999-09-24 JP JP2000571937A patent/JP4184607B2/ja not_active Expired - Lifetime
- 1999-09-24 BR BR9914051-9A patent/BR9914051A/pt not_active Application Discontinuation
- 1999-09-24 NZ NZ510690A patent/NZ510690A/xx not_active IP Right Cessation
- 1999-09-24 ES ES99949913T patent/ES2259845T3/es not_active Expired - Lifetime
- 1999-09-24 CN CNB998124982A patent/CN1150029C/zh not_active Ceased
- 1999-09-24 PL PL348328A patent/PL203689B1/pl unknown
- 1999-09-24 TR TR2001/00841T patent/TR200100841T2/xx unknown
- 1999-09-24 AT AT99949913T patent/ATE322280T1/de active
- 1999-09-24 PT PT60066974T patent/PT1674107T/pt unknown
- 1999-09-24 CN CNA200410031708XA patent/CN1530136A/zh active Pending
- 1999-09-24 EP EP06006697.4A patent/EP1674107B8/en not_active Expired - Lifetime
- 1999-09-24 HU HU0103874A patent/HU230656B1/hu unknown
- 1999-09-24 WO PCT/US1999/022366 patent/WO2000018419A2/en not_active Ceased
- 1999-09-24 CA CA002344318A patent/CA2344318C/en not_active Expired - Lifetime
- 1999-09-24 KR KR1020017003735A patent/KR20010075327A/ko not_active Ceased
- 1999-09-24 ES ES06006697.4T patent/ES2603086T3/es not_active Expired - Lifetime
- 1999-09-24 EP EP99949913A patent/EP1115417B1/en not_active Revoked
- 1999-09-24 PT PT99949913T patent/PT1115417E/pt unknown
- 1999-09-24 DE DE69930758T patent/DE69930758T2/de not_active Expired - Lifetime
-
2001
- 2001-03-14 IS IS5890A patent/IS5890A/is unknown
- 2001-03-22 NO NO20011454A patent/NO20011454L/no not_active Application Discontinuation
-
2002
- 2002-02-20 US US10/082,544 patent/US6852689B2/en not_active Expired - Lifetime
-
2003
- 2003-05-27 JP JP2003149968A patent/JP2003321389A/ja not_active Withdrawn
-
2004
- 2004-03-04 RU RU2004106569/14A patent/RU2363489C9/ru active
- 2004-08-17 JP JP2004237765A patent/JP2004339238A/ja not_active Withdrawn
-
2006
- 2006-04-18 CY CY20061100536T patent/CY1105556T1/el unknown
- 2006-06-23 NL NL300232C patent/NL300232I2/nl unknown
- 2006-06-28 LU LU91254C patent/LU91254I2/fr unknown
- 2006-07-18 CY CY200600003C patent/CY2006003I2/el unknown
- 2006-09-22 JP JP2006258107A patent/JP2006335773A/ja not_active Withdrawn
-
2009
- 2009-03-10 IS IS8807A patent/IS8807A/is unknown
-
2016
- 2016-11-24 CY CY20161101219T patent/CY1118334T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998022107A1 (fr) * | 1996-11-19 | 1998-05-28 | Rhone-Poulenc Rorer S.A. | Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation |
Non-Patent Citations (5)
| Title |
|---|
| CUBIST PRESS RELEASE, Cubist Pharmaceuticals initiates pivotal clinical trials for Daptomycin; novel antiinfective to treat serious life threatening infections, 1.mars 1999, Dated: 01.01.0001 * |
| J.R. WOODWORTH et al., Single-Dose Pharmacokinetics and Antibacterial Activity of Daptomycin, a New Lipopeptide Antibiotic, in Healthy Volunteers, Antimicrobial Agents and Chemotherapy, Feb. 1992, Vol 36 (2), side 218-325 * |
| J.R. WOODWORTH et al., Tobramycin and daptomycin disposition when co-administered to healthy volunteers, Journal of Antimicrobial Chemotherapy, 1994, Vol 33, side 655-659 * |
| OLESON Jr FB et al., Once-daily dosing decreases toxicity of daptomycin, Society of Toxicology Annual Meeting, 14.-18.mars 1999, side 322, abstract 1520, Dated: 01.01.0001 * |
| R.H.Baltz, Lipopeptide Antibiotics Produced by Streptomyces roseosporus and Streptomyces fradiae, Biotechnology of Antibiotics (Drugs and the Pharmaceutical Sciences) 2nd etition, 1997, side 415-435, Dated: 01.01.0001 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20011454L (no) | Fremgangsmåter ved administrering av antibiotika | |
| WO2002042462A3 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
| AP2004003069A0 (en) | 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof. | |
| FI973518A7 (fi) | Piperidinoalkanoliyhdistettä tai sen farmaseuttisesti hyväksyttävää suolaa sisltävä farmaseuttinen koostumus kiinteässä yksikköannosmuodossa | |
| CA2370030A1 (en) | Sodium channel blocker compositions and the use thereof | |
| ATE260658T1 (de) | Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen | |
| DK1201246T3 (da) | Anvendelse af trombopoietin som et medikament til behandling og forebyggelse af trombocytopeni | |
| KR970705553A (ko) | 디히드로벤조푸란, 및 항염증 약물로서 유용한 관련 화합물(dihydrobenzofuran and related compounds useful as anti-inflammatory agents) | |
| ES2160643T3 (es) | Composiciones que contienen g-csf y proteina de union al tnf. | |
| IL136733A0 (en) | Pharmaceutical composition containing sibutramine and orlistat | |
| GB2331926A (en) | Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine | |
| WO2002064214A3 (en) | Anti cancer combination of substituted pyrroles and paclitaxel | |
| HUP0000110A2 (hu) | Azaciklusos, azabiciklusos vagy tetrahidropiridinszármazékokat tartalmazó, fájdalom kezelésére alkalmas gyógyászati készítmények | |
| BG106180A (en) | Pharmaceutical composition containing sibutramine and orlistat | |
| SE9803623D0 (sv) | New therapeutic application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: CUBIST PHARMACEUTICALS LLC, US |
|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: CUBIST PHARMACEUTICALS LLC, US |
|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: CUBIST PHARMACEUTICALS LLC, CH |
|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |